At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
Ceftaroline +1 moredrug
Likely dose
Ceftaroline 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)
In Brief
A Phase 4 clinical trial evaluating Ceftaroline and Levofloxacin for Pneumonia, Bacterial and Community-acquired. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia, Bacterial, Community-acquired
CountriesUnited States
CollaboratorsForest Laboratories
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartFeb 2012
Primary CompletionMay 2014
Study CompletionApr 2015
TodayJul 2026
First PostedFeb 1, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMay 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.4 years ago
Interventions
Ceftarolinedrug
600 mg Q12h
Levofloxacindrug
750 mg QD